AnaptysBio, Inc. (ANAB)
Largest Insider Buys in Sector
ANAB Stock Price History Chart
ANAB Stock Performance
About AnaptysBio, Inc.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Insider Activity of AnaptysBio, Inc.
Over the last 12 months, insiders at AnaptysBio, Inc. have bought $10M and sold $5.83M worth of AnaptysBio, Inc. stock.
On average, over the past 5 years, insiders at AnaptysBio, Inc. have bought $32.15M and sold $6.16M worth of stock each year.
Highest buying activity among insiders over the last 12 months: EcoR1 Capital, LLC (10 percent owner) — $60M.
The last purchase of 273,972 shares for transaction amount of $10M was made by EcoR1 Capital, LLC (10 percent owner) on 2024‑08‑14.
List of Insider Buy and Sell Transactions, AnaptysBio, Inc.
| 2024-11-29 | Sale | director | 10,000 0.0329% | $25.00 | $250,000 | -6.35% | ||
| 2024-09-23 | Sale | Chief Medical Officer | 1,500 0.0054% | $38.67 | $58,005 | -30.85% | ||
| 2024-09-17 | Sale | CHIEF LEGAL OFFICER | 3,780 0.0128% | $38.41 | $145,191 | -33.23% | ||
| 2024-09-16 | Sale | Chief Medical Officer | 2,220 0.0074% | $38.93 | $86,425 | -35.12% | ||
| 2024-09-16 | Sale | CHIEF LEGAL OFFICER | 8,720 0.0297% | $39.82 | $347,270 | -35.12% | ||
| 2024-09-16 | Sale | CHIEF FINANCIAL OFFICER | 12,220 0.0417% | $39.91 | $487,725 | -35.12% | ||
| 2024-08-14 | Sale | Chief Medical Officer | 2,000 0.0088% | $40.00 | $80,000 | 0.00% | ||
| 2024-08-14 | 10 percent owner | 273,972 1.095% | $36.50 | $10M | 0.00% | |||
| 2024-07-18 | Sale | Chief Medical Officer | 1,500 0.0056% | $35.00 | $52,500 | -2.50% | ||
| 2024-07-15 | Sale | director | 10,000 0.0463% | $30.64 | $306,422 | 0.00% | ||
| 2024-06-21 | Sale | director | 1,950 0.007% | $23.17 | $45,182 | +39.96% | ||
| 2024-06-18 | Sale | director | 1,950 0.007% | $23.16 | $45,162 | +46.35% | ||
| 2024-05-22 | Sale | CHIEF FINANCIAL OFFICER | 1,500 0.0052% | $23.72 | $35,580 | +28.15% | ||
| 2024-03-25 | Sale | CEO | 3,000 0.0114% | $21.42 | $64,268 | +18.43% | ||
| 2024-03-22 | Sale | CEO | 145,940 0.5734% | $22.78 | $3.33M | +15.13% | ||
| 2024-02-16 | Sale | CHIEF LEGAL OFFICER | 5,000 0.0195% | $25.00 | $125,000 | +3.57% | ||
| 2024-01-30 | Sale | CHIEF FINANCIAL OFFICER | 3,065 0.0114% | $23.63 | $72,425 | +2.96% | ||
| 2024-01-08 | Sale | CEO | 6,866 0.0251% | $21.81 | $149,747 | +7.09% | ||
| 2024-01-08 | Sale | Chief Medical Officer | 2,554 0.0093% | $21.81 | $55,703 | +7.09% | ||
| 2024-01-08 | Sale | Chief Financial Officer | 2,180 0.008% | $21.81 | $47,546 | +7.09% |
Insider Historical Profitability
| EcoR1 Capital, LLC | 10 percent owner | 7794996 25.6172% | $15.09 | 10 | 0 | +15.76% |
| Faga Daniel | CEO | 749087 2.4618% | $15.09 | 0 | 3 | |
| Lizzul Paul F. | Chief Medical Officer | 15398 0.0506% | $15.09 | 0 | 6 | |
| MULROY DENNIS | CHIEF FINANCIAL OFFICER | 4744 0.0156% | $15.09 | 0 | 6 | |
| LOUMEAU ERIC J | CHIEF LEGAL OFFICER | 3240 0.0106% | $15.09 | 0 | 12 | |
| FENTON DENNIS M | director | 1950 0.0064% | $15.09 | 0 | 1 | |
| RENTON HOLLINGS | director | 1950 0.0064% | $15.09 | 0 | 3 | |
| NODELMAN OLEG | 7521024 24.7169% | $15.09 | 1 | 1 | +12.85% | |
| Novo Holdings A/S | 10 percent owner | 1936604 6.3644% | $15.09 | 1 | 8 | +58.88% |
| Topper James N | 1045031 3.4344% | $15.09 | 1 | 0 | +58.88% | |
| Frazier Healthcare V, LP | 10 percent owner | 311291 1.023% | $15.09 | 1 | 0 | +58.88% |
| Frazier Healthcare VII, L.P. | 10 percent owner | 311291 1.023% | $15.09 | 1 | 0 | +58.88% |
| Lydon Nicholas | director | 271106 0.891% | $15.09 | 1 | 1 | +58.88% |
| Suria Hamza | President, CEO | 68600 0.2254% | $15.09 | 0 | 10 | |
| Londei Marco | Chief Medical Officer | 22377 0.0735% | $15.09 | 0 | 3 | |
| Ware J. Anthony | director | 3600 0.0118% | $15.09 | 1 | 0 | +16.44% |
| Avalon Ventures VII L P | 10 percent owner | 0 0% | $15.09 | 0 | 1 | |
| Piscitelli Dominic | Chief Financial Officer | 0 0% | $15.09 | 0 | 1 |
Institutional Investor Ownership
| Ecor1 Capital Llc | $169.37M | 27.53 | 7.52M | 0% | +$0 | 1.19 | |
| BlackRock | $38.74M | 6.3 | 1.72M | -4.43% | -$1.8M | <0.01 | |
| The Vanguard Group | $30.49M | 4.96 | 1.35M | -1.89% | -$588,042.23 | <0.01 | |
| Tang Capital Management, LLC | $29.97M | 4.87 | 1.33M | -31.77% | -$13.96M | 0.11 | |
| Boxer Capital, LLC | $29.28M | 4.76 | 1.3M | 0% | +$0 | 0.6 | |
| State Street | $27.19M | 4.42 | 1.21M | +171.72% | +$17.18M | <0.01 | |
| Great Point Partners | $22M | 3.58 | 976,981 | 0% | +$0 | 3.69 | |
| First Light Asset Management | $21.26M | 3.46 | 944,110 | -23.69% | -$6.6M | 1.79 | |
| Frazier Life Sciences Management L P | $20.26M | 3.29 | 899,700 | 0% | +$0 | 0.92 | |
| Point72 Asset Management | $19.46M | 3.16 | 864,100 | +9.58% | +$1.7M | 0.03 | |
| Palo Alto Investors Lp | $18.01M | 2.93 | 799,906 | +16.45% | +$2.55M | 2.03 | |
| Mangrove Partners | $15.53M | 2.52 | 689,521 | New | +$15.53M | 0.16 | |
| Millennium Management LLC | $14.57M | 2.37 | 647,125 | +58.99% | +$5.41M | 0.01 | |
| Morgan Stanley | $14.33M | 2.33 | 636,114 | +5.66% | +$767,526.68 | <0.01 | |
| Saturn V Capital Management Llc | $13.2M | 2.15 | 586,031 | -11.78% | -$1.76M | 5.29 | |
| Deep Track Capital Lp | $11.92M | 1.94 | 529,452 | -74.01% | -$33.95M | 0.06 | |
| Woodline Partners LP | $11.46M | 1.86 | 508,839 | -57.42% | -$15.45M | 0.1 | |
| Dimensional Fund Advisors | $10.58M | 1.72 | 469,860 | -21.41% | -$2.88M | <0.01 | |
| Franklin Templeton Investments | $10.48M | 1.7 | 465,373 | +14.87% | +$1.36M | <0.01 | |
| Eventide Asset Management | $9.62M | 1.56 | 427,000 | 0% | +$0 | 0.16 | |
| Geode Capital Management | $9.5M | 1.54 | 421,703 | +0.38% | +$35,995.97 | <0.01 | |
| 5Am Venture Management Llc | $8.06M | 1.31 | 357,733 | 0% | +$0 | 0.54 | |
| Blackstone | $7.4M | 1.2 | 328,720 | 0% | +$0 | 0.03 | |
| Citadel Advisors LLC | $7.31M | 1.19 | 324,745 | +182.45% | +$4.72M | <0.01 | |
| Assenagon Asset Management S.A. | $5M | 0.81 | 221,838 | 0% | +$0 | 0.01 | |
| Northern Trust | $4.53M | 0.74 | 201,149 | -2.9% | -$135,097.50 | <0.01 | |
| D. E. Shaw & Co. | $4.21M | 0.68 | 186,804 | +16.52% | +$596,284.55 | <0.01 | |
| T. Rowe Price | $3.87M | 0.63 | 171,689 | -25.92% | -$1.35M | <0.0001 | |
| Octagon Capital Advisors LP | $3.72M | 0.6 | 165,000 | +37.5% | +$1.01M | 0.02 | |
| Goldman Sachs | $3.39M | 0.55 | 150,431 | +7.83% | +$246,143.59 | <0.01 | |
| Charles Schwab | $3.29M | 0.54 | 146,271 | +1% | +$32,676.52 | <0.01 | |
| Fidelity Investments | $3.17M | 0.52 | 140,746 | -30.57% | -$1.4M | <0.0001 | |
| Hudson Bay Capital Management LP | $2.98M | 0.49 | 132,500 | +39.47% | +$844,500.00 | 0.02 | |
| Two Sigma Advisers LP | $2.97M | 0.48 | 131,700 | +32.76% | +$731,900.00 | 0.01 | |
| Two Sigma | $2.7M | 0.44 | 119,971 | +37.06% | +$730,571.34 | <0.01 | |
| Renaissance Technologies | $2.26M | 0.37 | 100,200 | +4.81% | +$103,614.77 | <0.01 | |
| Macquarie Group | $2.11M | 0.34 | 93,732 | 0% | +$0 | <0.01 | |
| Rafferty Asset Management Llc | $2.04M | 0.33 | 90,694 | New | +$2.04M | 0.01 | |
| Ubs Oconnor Llc | $1.87M | 0.3 | 83,025 | -4.71% | -$92,309.48 | 0.09 | |
| Citigroup | $1.78M | 0.29 | 79,043 | +2,083.51% | +$1.7M | <0.01 | |
| Fisher Asset Management Llc | $1.59M | 0.26 | 70,654 | -0.7% | -$11,259.99 | <0.01 | |
| PLATINUM INVESTMENT MANAGEMENT LTD | $1.49M | 0.24 | 66,154 | New | +$1.49M | 0.02 | |
| Nuveen | $1.45M | 0.24 | 64,240 | +20.95% | +$250,557.55 | <0.0001 | |
| BNY Mellon | $1.44M | 0.24 | 64,087 | -8.49% | -$133,971.55 | <0.0001 | |
| UBS | $1.45M | 0.24 | 64,166 | +242.37% | +$1.02M | <0.0001 | |
| Wellington Management Company | $1.33M | 0.22 | 59,048 | New | +$1.33M | <0.0001 | |
| Bank of America | $1.23M | 0.2 | 54,525 | +114.54% | +$655,557.20 | <0.0001 | |
| Susquehanna Fundamental Investments Llc | $1.22M | 0.2 | 54,205 | New | +$1.22M | 0.05 | |
| Jacobs Levy Equity Management | $1.11M | 0.18 | 49,389 | +38.64% | +$309,965.20 | <0.01 | |
| Ensign Peak Advisors Inc | $978,314.00 | 0.16 | 43,442 | 0% | +$0 | <0.01 |